Corrigendum Free access | 10.1172/jci.insight.178762
Find articles by Fuentes-Mattei, E. in: JCI | PubMed | Google Scholar |
Find articles by Bayraktar, R. in: JCI | PubMed | Google Scholar |
Find articles by Manshouri, T. in: JCI | PubMed | Google Scholar
Find articles by Silva, A. in: JCI | PubMed | Google Scholar
Find articles by Ivan, C. in: JCI | PubMed | Google Scholar |
Find articles by Gulei, D. in: JCI | PubMed | Google Scholar
Find articles by Fabris, L. in: JCI | PubMed | Google Scholar
Find articles by Soares do Amaral, N. in: JCI | PubMed | Google Scholar
Find articles by Mur, P. in: JCI | PubMed | Google Scholar
Find articles by Perez, C. in: JCI | PubMed | Google Scholar
Find articles by Torres-Claudio, E. in: JCI | PubMed | Google Scholar
Find articles by Dragomir, M. in: JCI | PubMed | Google Scholar |
Find articles by Badillo-Perez, A. in: JCI | PubMed | Google Scholar
Find articles by Knutsen, E. in: JCI | PubMed | Google Scholar |
Find articles by Narayanan, P. in: JCI | PubMed | Google Scholar
Find articles by Golfman, L. in: JCI | PubMed | Google Scholar
Find articles by Shimizu, M. in: JCI | PubMed | Google Scholar
Find articles by Zhang, X. in: JCI | PubMed | Google Scholar
Find articles by Zhao, W. in: JCI | PubMed | Google Scholar
Find articles by Ho, W. in: JCI | PubMed | Google Scholar
Find articles by Estecio, M. in: JCI | PubMed | Google Scholar
Find articles by Bartholomeusz, G. in: JCI | PubMed | Google Scholar
Find articles by Tomuleasa, C. in: JCI | PubMed | Google Scholar
Find articles by Berindan-Neagoe, I. in: JCI | PubMed | Google Scholar
Find articles by Zweidler-McKay, P. in: JCI | PubMed | Google Scholar |
Find articles by Estrov, Z. in: JCI | PubMed | Google Scholar
Find articles by Zhao, Z. in: JCI | PubMed | Google Scholar
Find articles by Verstovsek, S. in: JCI | PubMed | Google Scholar
Find articles by Calin, G. in: JCI | PubMed | Google Scholar |
Find articles by Redis, R. in: JCI | PubMed | Google Scholar
Published February 8, 2024 - More info
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by cytopenia and extramedullary hematopoiesis, resulting in splenomegaly. Multiple pathological mechanisms (e.g., circulating cytokines and genetic alterations, such as JAKV617F mutation) have been implicated in the etiology of MF, but the molecular mechanism causing resistance to JAK2V617F inhibitor therapy remains unknown. Among MF patients who were treated with the JAK inhibitor ruxolitinib, we compared noncoding RNA profiles of ruxolitinib therapy responders versus nonresponders and found miR-543 was significantly upregulated in nonresponders. We validated these findings by reverse transcription–quantitative PCR. in this same cohort, in 2 additional independent MF patient cohorts from the United States and Romania, and in a JAK2V617F mouse model of MF. Both in vitro and in vivo models were used to determine the underlying molecular mechanism of miR-543 in MF. Here, we demonstrate that miR-543 targets the dioxygenases ten-eleven translocation 1 (TET1) and 2 (TET2) in patients and in vitro, causing increased levels of global 5-methylcytosine, while decreasing the acetylation of histone 3, STAT3, and tumor protein p53. Mechanistically, we found that activation of STAT3 by JAKs epigenetically controls miR-543 expression via binding the promoter region of miR-543. Furthermore, miR-543 upregulation promotes the expression of genes related to drug metabolism, including CYP3A4, which is involved in ruxolitinib metabolism. Our findings suggest miR-543 as a potentially novel biomarker for the prognosis of MF patients with a high risk of treatment resistance and as a potentially new target for the development of new treatment options.
Enrique Fuentes-Mattei, Recep Bayraktar, Taghi Manshouri, Andreia M. Silva, Cristina Ivan, Diana Gulei, Linda Fabris, Nayra Soares do Amaral, Pilar Mur, Cristina Perez, Elizabeth Torres-Claudio, Mihnea P. Dragomir, Adriana Badillo-Perez, Erik Knutsen, Pranav Narayanan, Leonard Golfman, Masayoshi Shimizu, Xinna Zhang, Wanke Zhao, Wanting Tina Ho, Marcos Roberto Estecio, Geoffrey Bartholomeusz, Ciprian Tomuleasa, Ioana Berindan-Neagoe, Patrick A. Zweidler-McKay, Zeev Estrov, Zhizhuang J. Zhao, Srdan Verstovsek, George A. Calin, Roxana S. Redis
Original citation JCI Insight. 2020;5(1):e121781. https://doi.org/10.1172/jci.insight.121781
Citation for this corrigendum: JCI Insight. 2024;9(3):e178762. https://doi.org/10.1172/jci.insight.178762
The authors became aware that the STAT3 and β-actin blots presented in Figure 4F appear to be the same. After review of the original data, the β-actin blot was determined to be incorrect due to an inadvertent error when assembling the final figure. The correct images were present in the original unedited blot and gel image document. The correct version of Figure 4F is shown below, and the HTML and PDF versions have been updated online. The Supplemental Data file has also been updated to correct an alignment issue in Supplemental Figure 7.
The authors regret the error.
See the related article at miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.